Annals of Clinical Biochemistry最新文献

Preβ1-HDL binds to TG-rich lipoproteins and its release is impaired in the postprandial state among patients with poorly controlled type 2 diabetes.

IF 2.1 4区医学

Annals of Clinical Biochemistry Pub Date : 2025-03-04 DOI: 10.1177/00045632251328154

Yuna Horiuchi, Satoshi Hirayama, Atsushi Hori, Yuri Ichikawa, Satoshi Soda, Utako Seino, Kazumasa Sekihara, Tsuyoshi Ueno, Yoshifumi Fukushima, Katsuo Kubono, Takashi Miida

{"title":"Preβ1-HDL binds to TG-rich lipoproteins and its release is impaired in the postprandial state among patients with poorly controlled type 2 diabetes.","authors":"Yuna Horiuchi, Satoshi Hirayama, Atsushi Hori, Yuri Ichikawa, Satoshi Soda, Utako Seino, Kazumasa Sekihara, Tsuyoshi Ueno, Yoshifumi Fukushima, Katsuo Kubono, Takashi Miida","doi":"10.1177/00045632251328154","DOIUrl":"https://doi.org/10.1177/00045632251328154","url":null,"abstract":"Background: Although preβ1-high-density lipoprotein (preβ1-HDL) promotes cholesterol efflux, high fasting preβ1-HDL levels after breakfast are reduced in patients with poorly controlled type 2 diabetes.Objective: This study investigated whether preβ1-HDL binds to triglyceride (TG)-rich lipoproteins (TGRLs) in the postprandial state and is released during lipolysis.Methods: We measured preβ1-HDL concentrations, lecithin-cholesterol acyltransferase (LCAT) activity, and LCAT-dependent preβ1-HDL conversion before and after breakfast in patients with diabetes. We also performed in vitro studies using TGRLs. Preβ1-HDL was quantified by enzyme-linked immunosorbent assay and native two-dimensional gradient gel (N-2D-gel) electrophoresis.Results: Before breakfast, the diabetes group had higher preβ1-HDL concentrations than the healthy controls; after breakfast, levels in the two groups were similar. Neither LCAT mass nor the LCAT-dependent preβ1-HDL conversion rate changed after breakfast. Mixing of fasting plasma with chylomicrons or very-low-density lipoprotein (VLDL) reduced the preβ1-HDL level by 15% ± 4% and 45% ± 10%, respectively. N-2D-gel electrophoresis showed that preβ1-HDL was generated by bacteria-derived TG lipase only from postprandial VLDL of patients with type 2 diabetes.Conclusion: Preβ1-HDL binds to TGRLs in the postprandial state and is released during lipolysis, implying that postprandial hyperlipidemia impairs reverse cholesterol transport in patients with poorly controlled type 2 diabetes.","PeriodicalId":8005,"journal":{"name":"Annals of Clinical Biochemistry","volume":" ","pages":"45632251328154"},"PeriodicalIF":2.1,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metamizole (dipyrone) as an interferent in biochemical assays.

IF 2.1 4区医学

Annals of Clinical Biochemistry Pub Date : 2025-03-04 DOI: 10.1177/00045632251328131

David Ceacero-Marín, Lídia Martínez-Zamorano, Adrián Gisbert-Alonso, Isabel Cachón-Suárez, Karla Gabriela Mendoza-Javier, María José Castro Castro

{"title":"Metamizole (dipyrone) as an interferent in biochemical assays.","authors":"David Ceacero-Marín, Lídia Martínez-Zamorano, Adrián Gisbert-Alonso, Isabel Cachón-Suárez, Karla Gabriela Mendoza-Javier, María José Castro Castro","doi":"10.1177/00045632251328131","DOIUrl":"https://doi.org/10.1177/00045632251328131","url":null,"abstract":"BACKGROUND Metamizole (MMZ), commonly used as an analgesic/antipyretic in countries like Spain, faces restrictions elsewhere due to side effects. Despite this, its frequent use underscores the critical importance of studying its impact on the accuracy of laboratory tests, particularly when blood samples are obtained shortly after intravenous administration. METHODS To investigate the in vitro interfering effect of MMZ, 20 serum biochemical assays were selected. The concentrations of biochemical assays were measured in a serum pool spiked with increasing MMZ concentrations. For each assay, the percentage of interference was calculated and compared with our laboratory's quality requirements for bias. In addition, it was assessed whether the interference was clinically significant. RESULTS In vitro interference was observed in some biochemical assays: cholesterol (CHOL), creatinine (CREA), high density lipoprotein cholesterol (HDL), lactate (LAC), lactate dehydrogenase (LDH), triglycerides (TG) and uric acid (UA), leading to falsely reduced results. All of them, except for the LDH assay, exhibited clinically significant interference with CREA being the first to be affected at a metamizole concentration of 0.31 g/L. No interference was observed in the remaining assays. CONCLUSIONS Falsely decreased and clinically significant CHOL, CREA, HDL, LAC, CHOL, TG and UA results were observed in serum samples due to in vitro interference caused by MMZ contamination. Serum concentrations in patients receiving intravenous MMZ treatment may be falsely decreased due to interference by MMZ. Knowledge of such interferences in clinical laboratories is crucial for the correct diagnosis and treatment of patients (1).","PeriodicalId":8005,"journal":{"name":"Annals of Clinical Biochemistry","volume":" ","pages":"45632251328131"},"PeriodicalIF":2.1,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Paired Copy Number Variation Analysis in Siblings Discordant for Familial Parkinson's Disease.

IF 2.1 4区医学

Annals of Clinical Biochemistry Pub Date : 2025-03-04 DOI: 10.1177/00045632251328130

Sevcan Atay, Ahmet Acarer, Handan Ak, Zafer Colakoglu, Hikmet Hakan Aydin

{"title":"Paired Copy Number Variation Analysis in Siblings Discordant for Familial Parkinson's Disease.","authors":"Sevcan Atay, Ahmet Acarer, Handan Ak, Zafer Colakoglu, Hikmet Hakan Aydin","doi":"10.1177/00045632251328130","DOIUrl":"https://doi.org/10.1177/00045632251328130","url":null,"abstract":"Objectives: Numerous studies on the genetic pathogenesis of familial Parkinson's Disease (PD) have explained the etiology of only a limited percentage of cases. In this study, we aimed to identify copy number variations (CNVs) in patients with familial PD compared to their healthy siblings.Methods: Genomic microarray analysis was performed using the CytoScan HD array platform, and paired copy number variation analysis was performed using Partek Genomics Suite.Results: A total of 211 CNVs were detected in patients (genomic markers per CNV>10, markers per base pair >0.0005). Genes localized in CNV regions were enriched in the 'Metabolism of xenobiotics by cytochrome P450' pathway. Subsequently, CNVs located in regions with segmental duplication, large genomic gap or 'dosage sensitivity unlikely ', with a frequency higher than 0.01%, and found to be 'both amplified and deleted' in patients were excluded. Genes potentially affected by exonic copy number losses were HPGDS, TUBB8, ZMYND11, FLI-1, THADA, FAM47E, FAM47E-STBD1, AGMO, CYRIB, and MIR5194, while the detected copy number gains included the exons of the PCSK6, MIR4522, WSB1, C8orf44-SGK3, SGK3, and MCMDC2. No copy number variation was detected in chromosomes 13 and 18.Conclusions: Here, we report the results of the first paired CNV analysis in siblings discordant for Familial Parkinson's Disease. Validation and frequency determination of rare and novel CNVs identified in larger familial PD cohorts may reveal novel PH risk genes. The metabolism of xenobiotics by cytochrome P450 pathway deserves further functional and translational studies in familial Parkinson's disease.","PeriodicalId":8005,"journal":{"name":"Annals of Clinical Biochemistry","volume":" ","pages":"45632251328130"},"PeriodicalIF":2.1,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ubiquitin C-terminal Hydrolase-L1 and Glial Fibrillary Acidic Protein Tandem Brain Biomarker Test in the Prediction of CT Evident Brain Injury: a Prospective Evaluation in the Emergency Department.

IF 2.1 4区医学

Annals of Clinical Biochemistry Pub Date : 2025-02-28 DOI: 10.1177/00045632251326483

Jemima M Curran, Katherine Onions, Jessica Watts, Arnab Rana, Emma Hughes, Jim Allison, Jamie G Cooper

{"title":"Ubiquitin C-terminal Hydrolase-L1 and Glial Fibrillary Acidic Protein Tandem Brain Biomarker Test in the Prediction of CT Evident Brain Injury: a Prospective Evaluation in the Emergency Department.","authors":"Jemima M Curran, Katherine Onions, Jessica Watts, Arnab Rana, Emma Hughes, Jim Allison, Jamie G Cooper","doi":"10.1177/00045632251326483","DOIUrl":"https://doi.org/10.1177/00045632251326483","url":null,"abstract":"Patients with features of mild traumatic brain injury (mTBI) frequently present to the emergency department (ED) and often meet recognised criteria for CT head imaging. Observational studies suggest that use of a tandem ubiquitin C-terminal hydrolase-L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) brain biomarker test may significantly reduce need for CT scanning in this population, though data on patient flow are lacking. In a prospective evaluation in a UK population with mTBI a laboratory UCH-L1/GFAP test identified 21 of 89 (24%) patients as low-risk for CT-evident TBI with a sensitivity of 100% (95% CI 76-100%) and NPV of 100% (95% CI 85-100%). The median time to obtain a biomarker result from venesection was 88 minutes, similar to the time from CT request to report (89 minutes). However, those 68 (76%) patients with a positive biomarker result would all have required subsequent CT imaging, significantly prolonging ED length of stay and making incorporation into clinical pathways difficult. Availability of platforms that allow measurement of UCH-L1/GFAP in whole blood at the point-of-care may circumvent these problems in the future, and permit safe rationalisation of CT imaging in this population without compromising ED patient workflows.","PeriodicalId":8005,"journal":{"name":"Annals of Clinical Biochemistry","volume":" ","pages":"45632251326483"},"PeriodicalIF":2.1,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A multicenter study comparing a point-of-care blood glucose meter with a blood gas analyzer in infants by the Shikoku Neonatal Medical Research Group.

IF 2.1 4区医学

Annals of Clinical Biochemistry Pub Date : 2025-02-28 DOI: 10.1177/00045632251326460

Toru Kuboi, Masashiro Sugino, Takaaki Sadamura, Nana Kawaguchi, Yoko Tadatomo, Kosei Takada, Natsumi Okamoto, Kiwako Miyamoto, Akiko Nakano, Noriko Miura, Yusei Nakata, Kenichi Suga, Masaaki Ota, Shinji Nakamura, Kosuke Koyano, Takashi Kusaka

{"title":"A multicenter study comparing a point-of-care blood glucose meter with a blood gas analyzer in infants by the Shikoku Neonatal Medical Research Group.","authors":"Toru Kuboi, Masashiro Sugino, Takaaki Sadamura, Nana Kawaguchi, Yoko Tadatomo, Kosei Takada, Natsumi Okamoto, Kiwako Miyamoto, Akiko Nakano, Noriko Miura, Yusei Nakata, Kenichi Suga, Masaaki Ota, Shinji Nakamura, Kosuke Koyano, Takashi Kusaka","doi":"10.1177/00045632251326460","DOIUrl":"https://doi.org/10.1177/00045632251326460","url":null,"abstract":"Background: There have been no reports on blood glucose meters for measurements in a wide variety of infant patients, from very preterm infants to mature infants and from the early neonatal period onwards. In this study, we evaluated the accuracy of the Glutest Mint II, a point-of-care blood glucose meter, by comparing blood glucose levels measured by this device with those measured by a blood gas analyzer in infants of all gestational ages and birth weights at a number of time points after birth.Methods: Infants aged 22 weeks and 0 days of gestation or older who were born at any of six tertiary neonatal intensive care units between March 2022 and January 2023 and needed blood glucose monitoring were enrolled. Samples were collected into capillary tubes when the physician determined that a blood glucose test was necessary and could be taken at any time after birth and any number of times from the same individual. Blood glucose was measured using a Glutest Mint II and then using a blood gas analyzer.Results: In total, 2,943 blood glucose points were measured in 285 infants. Blood glucose levels measured using the Glutest Mint II were significantly correlated with those measured using a blood gas analyzer. Neonatal-specific parameters such as hematocrit and total serum bilirubin levels may not have an effect.Conclusions: The Glutest Mint II device can measure blood glucose levels with very high accuracy in the range used in the neonatal setting, comparable to the blood gas analyzer.","PeriodicalId":8005,"journal":{"name":"Annals of Clinical Biochemistry","volume":" ","pages":"45632251326460"},"PeriodicalIF":2.1,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Determination of the biological variation and reference change value of lipoprotein (a).

IF 2.1 4区医学

Annals of Clinical Biochemistry Pub Date : 2025-02-25 DOI: 10.1177/00045632251324063

Kofi Antwi, Paul Downie, Wycliffe Mbagaya

{"title":"Determination of the biological variation and reference change value of lipoprotein (a).","authors":"Kofi Antwi, Paul Downie, Wycliffe Mbagaya","doi":"10.1177/00045632251324063","DOIUrl":"10.1177/00045632251324063","url":null,"abstract":"Background: Understanding lipoprotein (a) [Lp(a)] measurement variability is essential in establishing its coronary heart disease (CHD) association, and optimizing assessment and management of atherosclerotic cardiovascular disease (ASCVD) risk. We established the components of biological variation (BV) and reference change value (RCV) of Lp(a) in a UK cohort.Method: 22 healthy individuals were recruited to the study. Blood samples were collected for six consecutive weeks and analysed in duplicate using the Lp(a) assay by Sentinel Diagnostics on the Beckman Coulter AU5800. Outlier, heterogeneity, normality, and trend analysis were performed, followed by CV-ANOVA to determine estimates of BV, adhering to the 14 BIVAC quality items. RCV was calculated based on estimated CVA and CVI.Results: Four participants were excluded from the analysis as their mean Lp(a) levels fell below the functional sensitivity of the assay. Mean Lp(a) concentration ranged from 14 to 241 nmol/L. The overall estimate of CVI for all participants was 10.9% (95% CI of 9.1 - 13.0%). The RCV for Lp(a) was +31.6%/-24.0%.Conclusion: Our study obtained a CVI estimate for Lp(a) that aligned consistently with recent studies adhering to the quality specifications outlined in the BIVAC checklist. The CVI estimate was significantly lower than Lp(a) estimates reported in studies up to 2003. The CVI estimate highlights the limitations of relying solely on a single Lp(a) measurement for prognosticating ASCVD risk and identifying candidates for novel Lp(a) therapies, particularly when the measured value is near clinical decision thresholds.","PeriodicalId":8005,"journal":{"name":"Annals of Clinical Biochemistry","volume":" ","pages":"45632251324063"},"PeriodicalIF":2.1,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metronidazole is a chromatographic interference on a routine HPLC-UV assay for thiopurine metabolites.

IF 2.1 4区医学

Annals of Clinical Biochemistry Pub Date : 2025-02-21 DOI: 10.1177/00045632251319917

Andrew A Wood, Sophie Rothwell Mason, Anna F Robson

{"title":"Metronidazole is a chromatographic interference on a routine HPLC-UV assay for thiopurine metabolites.","authors":"Andrew A Wood, Sophie Rothwell Mason, Anna F Robson","doi":"10.1177/00045632251319917","DOIUrl":"10.1177/00045632251319917","url":null,"abstract":"Background: Thiopurine metabolites, 6-thioguanine (6TG) and 6-methylmercaptopurine (6MMP), are monitored to aid therapeutic management of thiopurine drugs. At Manchester University NHS Foundation Trust (MFT), thiopurine metabolites are measured by high performance liquid chromatography with ultraviolet detection (HPLC-UV). Whole blood samples are lysed and subjected to hydrolysis with derivatisation of 6MMP before HPLC-UV detection at 304 nm for the 6MMP-derivative and 342 nm for 6TG. For some samples, 6MMP cannot be reported due to a chromatographic interference at 304 nm co-eluting with the 6MMP peak. An investigation was performed to identify the interfering compound.Methods: Patient medication histories were examined to identify candidate compounds for the interference. Candidate compounds were spiked into blood at supraphysiological concentrations and tested on the assay.Results: Metronidazole was identified as being prescribed to all patients whose samples demonstrated the interference. Metronidazole and its metabolite, hydroxymetronidazole, were spiked into blood. HPLC-UV analysis of spiked blood demonstrated similar UV absorbance patterns to those seen in patient samples with the interference. Hydroxymetronidazole co-eluted with 6MMP causing interference in the measurement.Conclusion: Metronidazole and its major metabolite can interfere with 6MMP measurement by HPLC-UV analysis at 304 nm.","PeriodicalId":8005,"journal":{"name":"Annals of Clinical Biochemistry","volume":" ","pages":"45632251319917"},"PeriodicalIF":2.1,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143057759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Falsely elevated type IV collagen caused in part by heterophilic antibodies: A case report.

IF 2.1 4区医学

Annals of Clinical Biochemistry Pub Date : 2025-02-20 DOI: 10.1177/00045632251322316

Xian-Min Lv, Long Xiao, Hong-Lei Yu, Lu-Wei Yan

{"title":"Falsely elevated type IV collagen caused in part by heterophilic antibodies: A case report.","authors":"Xian-Min Lv, Long Xiao, Hong-Lei Yu, Lu-Wei Yan","doi":"10.1177/00045632251322316","DOIUrl":"https://doi.org/10.1177/00045632251322316","url":null,"abstract":"Immunoassays, which are used ubiquitously in clinical practice, are inherently vulnerable to distortions arising from endogenous immunoglobulins, particularly heterophilic antibodies. While many studies have explored interference in substances measured using chemiluminescence or electrochemiluminescence methods based on the double-antibody sandwich principle, there are limited data on interference in immunoturbidimetric assays, particularly for type IV collagen. This article presents the first report of a noteworthy increase in serum type IV collagen levels stemming from heterophilic antibody interference detected through an immunoturbidimetric assay. The present study investigated the mechanisms of this interference and the differences introduced by heterophilic antibodies between the two methodologies. Additionally, it outlines strategies for identifying and mitigating such interference, and discusses the principles, limitations, and considerations of each corrective approach. The objective is to raise awareness among clinical laboratory professionals concerning the potential interference of heterophilic antibodies in immunoturbidimetric assays. Increased awareness will aid in the prompt detection and correction of this issue, ensuring the provision of accurate and reliable laboratory data for informed clinical decision-making and the prevention of adverse medical outcomes.","PeriodicalId":8005,"journal":{"name":"Annals of Clinical Biochemistry","volume":" ","pages":"45632251322316"},"PeriodicalIF":2.1,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143456743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A United Kingdom-wide audit of the laboratory investigation of primary aldosteronism.

IF 2.1 4区医学

Annals of Clinical Biochemistry Pub Date : 2025-02-13 DOI: 10.1177/00045632251319984

Sarah L Davies, Daniel J Cuthbertson, Louise J Ward, Wassif S Wassif, Mark Gurnell, Andrew S Davison

{"title":"A United Kingdom-wide audit of the laboratory investigation of primary aldosteronism.","authors":"Sarah L Davies, Daniel J Cuthbertson, Louise J Ward, Wassif S Wassif, Mark Gurnell, Andrew S Davison","doi":"10.1177/00045632251319984","DOIUrl":"10.1177/00045632251319984","url":null,"abstract":"Objectives: Primary aldosteronism (PA) is a common but under-recognised cause of secondary hypertension. Early diagnosis with targeted medical and/or surgical intervention is important to prevent irreversible end-organ damage. An Endocrine Society Clinical Practice Guideline was used to define audit standards against which to assess current United Kingdom (UK) laboratory practice.Methods: A survey comprising 22 questions, which captured information on screening, confirmatory testing and adrenal vein sampling (AVS), was distributed to all UK Clinical Biochemistry laboratories by the Association for Laboratory Medicine. Consultation with clinical colleagues was encouraged.Results: 50 of 147 laboratories (34.0%) responded, 17 of which provided an analytical service for plasma aldosterone concentration (PAC) and renin, measured as plasma renin activity (PRA) or direct renin concentration (DRC). PRA/DRC, PAC and aldosterone:renin ratios were used to screen for PA. Saline infusion testing was the most common confirmatory test. AVS was used to aid lateralisation. Chemiluminescence immunoassay and liquid chromatography tandem mass spectrometry were the preferred analytical methods for PAC and PRA/DRC. However, there was considerable variation across centres in respect of reference intervals and cutoffs, which were not fully accounted for by differences in analytical platforms. Although diagnostic algorithms, with pre- and post-analytical support, were in evidence in some centres, these were not universal or always embedded in a multidisciplinary team setting.Conclusions: We observed significant heterogeneity in the laboratory investigation of PA across the United Kingdom. Therefore, this work serves as a stimulus for greater collaboration to permit national harmonisation/standardisation of analytical and clinical aspects of UK PA practice.","PeriodicalId":8005,"journal":{"name":"Annals of Clinical Biochemistry","volume":" ","pages":"45632251319984"},"PeriodicalIF":2.1,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143057758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Standardising lipid testing and reporting in the United Kingdom; a joint statement by HEART UK and The Association for Laboratory Medicine. 英国血脂检测和报告标准化；英国心脏协会和检验医学协会的联合声明。

IF 2.1 4区医学

Annals of Clinical Biochemistry Pub Date : 2025-01-31 DOI: 10.1177/00045632251315303

Julia S Kenkre, Tina Mazaheri, R Dermot G Neely, Handrean Soran, Dev Datta, Peter Penson, Paul Downie, Alexandra M Yates, Katharine Hayden, Mayur Patel, Jaimini Cegla

{"title":"Standardising lipid testing and reporting in the United Kingdom; a joint statement by HEART UK and The Association for Laboratory Medicine.","authors":"Julia S Kenkre, Tina Mazaheri, R Dermot G Neely, Handrean Soran, Dev Datta, Peter Penson, Paul Downie, Alexandra M Yates, Katharine Hayden, Mayur Patel, Jaimini Cegla","doi":"10.1177/00045632251315303","DOIUrl":"10.1177/00045632251315303","url":null,"abstract":"Atherosclerotic cardiovascular disease remains a major cause of premature death in the United Kingdom. Lipid testing is a key tool used to assess cardiovascular risk and guide clinical management decisions. There are currently no national guidelines to provide evidence-based recommendations on lipid testing and reporting for UK laboratories and clinicians. Here we present consensus guidance, following a review of published evidence by a multidisciplinary group of UK experts across a range of laboratory and clinical services. Recommendations include the composition of a standard lipid profile; indications for, and composition of, an enhanced lipid profile including apolipoprotein B and lipoprotein (a); use of the Sampson-NIH calculation for LDL-c estimation and guidance on when to flag abnormal results. This consensus guidance on lipid testing and reporting in the United Kingdom has been endorsed by HEART UK and The Association for Laboratory Medicine.","PeriodicalId":8005,"journal":{"name":"Annals of Clinical Biochemistry","volume":" ","pages":"45632251315303"},"PeriodicalIF":2.1,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142943256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0